Peripheral helper lymphocytes produce interleukin 12 in cancer patients

Clinical Medicine Insights: Oncology

Volumn 7, Issue , 2012, Pages 75-81

  Michelin, Márcia A ^a   Abdalla, Douglas R ^a   Aleixo, André A R ^a   Murta, Eddie F C ^a  

^a FEDERAL UNIVERSITY OF TRIÂNGULO MINEIRO   (Brazil)

Author keywords

Cancer; Immune response; Interleukin 12; T lymphocyte

Indexed keywords

INTERLEUKIN 12;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER PATIENT; CD4+ T LYMPHOCYTE; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EX VIVO STUDY; FEMALE; FOLLOW UP; HELPER CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; LUNG CANCER; MALE; MELANOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR IMMUNITY; UPREGULATION; UTERINE CERVIX CARCINOMA IN SITU; UTERUS SARCOMA;

EID: 84874856705     PISSN: 11795549     EISSN: None     Source Type: Journal    
DOI: 10.4137/CMO.S11292     Document Type: Article

References (31)

1. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 1989;7:145-73.
2. Dileepan KN, Page JC, Li Y, Stechschulte DJ. Direct activation of murine peritoneal macrophages for nitric oxide production and tumor cell killing by interferon-gamma. J Interferon Cytokine Res. 1995;15(5):387-94.
3. Kidd P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev. 2003;8(3):223-46.
4. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009;361(9):888-98.
5. Bais AG, Beckmann I, Ewing PC, et al. Cytokine release in HR-HPV(+)women without and with cervical dysplasia (CIN II and III) or carcinoma, compared with HR-HPV(-) controls. Mediators Inflamm. 2007;2007: 24147. doi: 10.1155/2007/24147.
6. Podgaec S, Abrao MS, Dias JA, et al. Endometriosis: an inflammatory disease with a Th2 immune response component. Human Reproduction. 2007;22(5):1373-9.
7. Bettelli E, Korn T, Oukka M, Kuchroo VK. Induction and effector functions of TH17 cells. Nature. 2008;453(7198):1051-7.
8. Elyaman W, Bradshaw EM, Uyttenhove C. IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc Natl Acad Sci U S A. 2009;31:12885-90.
9. Josefowicz SZ, Rudensky A. Controlo f regulatory T cell lineage commitent and maintenance. Immunity. 2009;30:616-25.
10. Trifari S, Kaplan CD, Tran EH, Crellin NK, Spits H. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from TH-17, TH-1 and TH-2 cells. Nat Immunol. 2009;10:864-71.
11. Guedes PMM, Gutierrez FRS, Maia FL, et al. IL-17 produced during trypanosoma cruzi infection plays a central role in regulating parasite-induced myocarditis. PLoS Negl Trop Dis. 2010;4:e604.
12. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol. 2009;27:485-517.
13. Li H, Rostami A. IL-9: Basic biology, signaling pathways in CD4+ T cells and implications for autoimmunity. J Neur Pharmacology. 2010;5: 198-209.
14. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen specific adaptive immunity. Annu Rev Immunol. 1995;13:251-76.
15. Zhang J, Zhu N, Wang Q, et al. MEKK3 overexpression contributes to the hyperresponsiveness of IL-12-overproducing cells and CD4+ T conventional cells in nonobese diabetic mice. J Immunol. 2010;185:3554-63.
16. Lauwerys BR, Renauld JC, Houssiau FA. Synergistic proliferation and activation of natural killer cells by interleukin-12 and interleukin-18. Cytokine. 1999;11(11):822-30.
17. Robinson D, Shibuya K, Mui A, et al. IGIF does not drive Th1 development but synergizes with IL-12 for interferon-γ production and activates IRAK and NF-γB. Immunity. 1997;7(4):571-81.
18. Hung K, Hayashi R, Lafond-Walker A, et al. The central role of CD4+ T cells in the antitumor immune response. J Exp Med. 1998;188:2357-68.
19. Tatsumi T, Huang J, Gooding WE, et al. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. Cancer Res. 2003;63:78-86.
20. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960-4.
21. Rodrigues CM, Matias BF, Murta EF, Michelin MA. The role of T lymphocytes in cancer patients undergoing immunotherapy with autologous dendritic cells. Clin Med Insights Oncol. 2011;5:107-15.
22. Leavitt RD, Felsted RL, Bachur NR. Biological and biochemical properties of Phaseolus vulgaris isolectinas. J Biol Chem. 1977;252(9):2961-6.
23. Ovstebo R, Olstad OK, Brusletto B, et al. Identification of genes particularly sensitive to lipopolysaccharide (LPS) in human monocytes induced by wild-type versus LPS-deficient Neisseria meningitidis strains. Infect Immun. 2008;76:2685-95.
24. Kerkar SP, Muranski P, Kaiser A, et al. Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res. 2010;70(17):6725-34.
25. Wesa A, Kalinski P, Tatsumi T, et al. Polarized type-1 cells (DC1) producing high levels of IL-12 family members rescue patient Th1-type anti-melanoma CD4+ T cell responses in vitro. J Immunother. 2007;30:75-82.
26. Colombo MP, Trinchieri G. Interleukin-12 in antitumor immunity and immunotherapy. Cytokine Growth Factor Rev. 2002;13:155-68.
27. Zilocchi C, Stoppacciaro A, Chiodoni C, et al. Interferon gamma-independent rejection of interleukin 12-transduced carcinoma cells requires CD4+ T cells and Granulocyte/Macrophage colony-stimulating factor. J Exp Med. 1998;188(1):133-43.
28. Cavallo F, Signorelli P, Giovarelli M, et al. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J Natl Cancer Inst. 1997;89:1049-58.
29. Ramos MC, Mardegan MC, Peghini BC, Adad SJ, Michelin MA, Murta EF. Expression of cytokines in cervical stroma in patients with high-grade cervical intraepithelial neoplasia after treatment with intralesional interferon α-2b. Eur J Gynaecol Oncol. 2010;31(5):522-9.
30. Mardegan MC, Ramos MC, Adad SJ, Michelin MA, Shimba D, Murta EF. Immunological evaluation of vaginal secretion in patients with high-grade cervical intra-epithelial neoplasia treated with intralesional interferon α-2b. Eur J Gynaecol Oncol. 2011;32:297-302.
31. Misson DR, Abdalla DR, Borges AM, et al. Cytokine serum levels in patients with cervical intraepithelial neoplasia grade II-III treated with intralesional interferon-α 2b. Tumori. 2011;97:580-6.